The insider sales are too small to be a meaningful signal. Focus on the Q2 beat and Cortrophin Gel trajectory, the narrowed guidance for Cortrophin is the key risk to monitor.
Drug in focus
ANIP drug pipeline →Cortrophin Gel
▲ Bullish Named in this insider cluster- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available since January 2022.
- Next catalyst
- None dated
What to watchCortrophin Gel is already approved and commercialized with no pending regulatory binary. The key near-term catalysts are commercial execution metrics: Q4 2026 Cortrophin revenue (expected early Feb 2027) will show whether the specialty pharmacy capacity constraints that slowed Q3 conversion have resolved, and whether the gout sales force expansion is gaining traction. The Egetis/EMCITATE acquisition acceptance period (Nov 20-Dec 18, 2026) is a separate corporate event that could affect ANIP's balance sheet and rare disease strategy.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $76.54entry
- T+1 · 3mo ago −0.71%α −0.23% · $76.00
- T+5 · 3mo ago −1.55%α −0.19% · $75.35
- T+20 · 2mo ago −8.02%α −6.03% · $70.40
- T+60 · 13d ago −11.43%α −8.39% · $67.79
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two ANIP insiders sold a combined $281K in open-market sales over a 7-day window following a strong Q2 earnings beat. The sales are small relative to the $1.7B market cap (0.017%), and the cluster is likely driven by post-earnings blackout window opening and routine portfolio diversification rather than a bearish signal. The earnings beat and reaffirmed guidance provide a positive backdrop, but the insider sales temper the bullish read.
Key Financial Metrics
Key Facts
- Two insiders sold a total of $281K in open-market sales from Aug 6-13, 2026.
- Sales represent 0.017% of ANIP's $1.7B market cap, well below the 0.1% materiality threshold.
- Q2 2026 revenue of $266.0M (+25.9% YoY) beat consensus of $260.1M; adjusted EPS of $2.21 beat $2.04 estimate.
- Cortrophin Gel revenue surged 43.5% to $117.1M, but full-year Cortrophin guidance was narrowed to $520-$540M from $540-$575M.
Financial Impact
Insider sales of $281K, or 0.017% of market cap, immaterial in absolute and relative terms.
Risk Factors
- Cortrophin Gel guidance narrowed to $520-$540M from $540-$575M, signaling potential demand deceleration.
- Insider sales, while small, could indicate insiders are taking advantage of the post-earnings price strength.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ANIP-1786691014960 |
Track record
34 reports on ANIP
4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 12 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers